Archives for the month of: July, 2016

Following the publication last week of the Home Office statistics on the use of animals in scientific procedures, today’s video comes from Imperial College London and details how they use animals as part of their research.

Do you have a video you would like the sector to see? Contact us.

Q2 2016 reportOngoing BIA engagement enables our members’ voices to be heard at the highest levels. Our latest quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from April to July 2016.

In the update, you can read up on key issues for the life sciences industry such as:

The EU Referendum, the new Government and the life sciences industry – Following the EU Referendum result, the BIA has acted swiftly to position our sector at the heart of Government thinking as events and Brexit discussions continue to unfold. Find out more about the formation of the UK EU Life Sciences Steering Group, set up to oversee and manage the transition for the sector.

The political fallout from the EU referendum result ushered in a new Prime Minister sooner than many expected. The former Home Secretary, Theresa May, entered Downing Street on 13 July and quickly set about establishing a new Government with a ministerial reshuffle and rearrangement of Whitehall departments. Published alongside the quarterly update, the BIA has produced a quick briefing for members on the new Government and key ministerial appointments. It will be updated as information emerges. You can download the guide here.

May Cabinet

Changes to innovation support not slowed by Brexit – The Government is pressing ahead with the reorganisation of the UK’s research and innovation system, including bringing the operation of Innovate UK and the seven Research Councils closer together. In addition, the announcement of a £10m Biomedical Catalyst competition for 2016 is welcome news that Innovate UK and the Government are listening to the BIA’s calls for an effective innovation policy for the life sciences.

28144680336_8a00f60fc5_oBIA Parliament Day – On 7 July 2016, 35 senior representatives from the UK’s life science industry convened for the BIA’s sixteenth annual Parliament Day – a key day of engagement between BIA members and policymakers in Whitehall and Westminster.

BIA briefing paper on orphan medicinal products – In May the BIA launched a briefing paper on Orphan Medicinal Products that looked into the 15 year application of the Orphan Regulation in Europe. The paper coincided with the European Conference on Rare Diseases and Orphan Products, which was held in the UK for the first time.

BIA-MHRA joint regulatory conference 2016 – The BIA and MHRA have published a report following their sixth annual joint conference, Accelerated Development and Access to Innovative Medicines for Patients, which took place on 4 May 2016. BIA and MHRA brought together experts from across the sector to assess the state of play, discuss how the various schemes have performed, and how the NHS might respond to current innovation challenges.

Ian Hudson quote

BIA welcomes new NHS report on access to biosimilar medicines – The BIA has welcomed the recent publication of the report of the biosimilar medicines workshops hosted by NHS England in coordination with a range of national partners. The BIA has partnered with NHS England in developing this document and is a member of the National Biosimilar Medicines Programme Board, which will be considering how to prioritise and advance the proposed next steps arising from the workshops.

For details on the above topics and more, download our latest quarterly update, Influencing and Shaping Our Sector: BIA update April – July 2016.

To learn more about BIA’s policy, public affairs and regulatory affairs work, see our previous quarterly policy updates, our consultation responses, or email Zoë with any questions.

Our latest BIA member webinar took place earlier this month, focussing on how to raise capital while retaining control. BIA CEO Steve Bates was joined by three key biotech CEO’s who provided an overview of their experience: Darrin Disley detailed how Horizon Discovery was able to bring in different types of capital at different stages of the business; Harren Jhoti covered the potential of mergers and acquisitions following his experience at Astex Pharmaceuticals; and Neil Murray spoke about the evolution of Redx Pharma and their collaboration with the NHS. Read on to find out more…

The BIA’s recently published report, Money, momentum and maturity, provides an overview of the current financing environment in UK biotech. The report details encouraging trends in follow-on funding, venture capital activity, the strength of the R&D pipeline and rate of regulatory approvals which are promising as we look to develop the UK as the third global biotech cluster. Investors’ appetite for venture finance was stronger than ever in 2015 with £489m raised, accounting for over a third of the European total. 2015 also saw an impressive level of follow-on funding raised by biotech companies on the LSE.

With many methods available to raise capital in the industry, each guest speaker on the webinar was invited to tell their own experience, describing the route they took.

First to speak, Dr Darrin Disley of Horizon Discovery outlined his approach to attracting different types of capital at different stages of the business, aligning their funding with the growth and market of the business. Horizon Discovery has utilised a number of different funding options, including angel investors, corporate investment and venture capital. In March 2014, Horizon Discovery completed an IPO on AIM, returning money to their pre-IPO investors. More recently, the company has raised capital through a follow-on on the public markets, money which is now being invested to drive forward the growth of the company.

Taking a different approach, Dr Harren Jhoti of Astex Pharmaceuticals discussed the option of a merger or acquisition as a means to raise capital. In 2011, after dismissing the option of an IPO due to the financial climate, the company underwent a merger with SuperGen – a Nasdaq listed company. The merger represented significant capital in terms of future royalty streams and was also a company building exercise. A few years later, in 2013, Astex was acquired by Japan’s Otsuka.

Discussing the pros and cons of M&A, Harren highlighted the importance of Board composition with regards to retaining control. In the case of a small company being acquired, there is a danger of losing this control and becoming swamped or integrated into a large organisation. For Astex, the company was able to secure assurances that its name would survive the transaction and they would continue to have a significant level of operational independence. As such the company is as a wholly owned subsidiary of Otsuka but runs effectively as a small biotech company.

Finally, Dr Neil Murray of Redx Pharma detailed the benefits and challenges of raising capital through high net worth investors, the company’s primary source of capital up until its IPO last year. When dealing with this type of investment, Neil highlighted the importance of ensuring you provide enough feedback to the investors to showcase the company’s development – nothing succeeds like delivery.

Neil also spoke about the evolution of Redx Pharma and their opportunistic collaboration with the NHS, which helped to bring in just under £6M of funding.

The webinar finished with a Q&A for each of our speakers, with Steve Bates asking what people should be thinking about in the current climate. Each panellist agreed that people will continue to invest in good ideas, whatever the environment. There’s money to be had in the sector and companies should continue to reach for it!

For more details and to hear the Q&A, watch the webinar below.

2015 animal stats

Details about ministerial responsibilities continue to trickle out of Whitehall. It now looks highly likely that George Freeman MP will not be replaced by a new dedicated Life Sciences Minister. Instead, we believe responsibility for life sciences will be split between Health and Business Ministers. In the Department of Health, Lord Prior has responsibility for the life sciences industry and Nicola Blackwood has responsibility for life sciences innovation, along with data and technology. It has not yet been confirmed whether the Universities and Science Minister, Jo Johnson MP, will also have responsibility for our sector in the new Department for Business, Energy and Industrial Strategy (BEIS) or if it will go to one of his colleagues. We are continuing to engage with Government at all levels to determine responsibilities and ensure life sciences has a strong voice. Keep a look out for our guide to the new Government for BIA members, which we will publish later this week, alongside our latest Quarterly Report.

Many of you will have seen comments made by Jeremy Corbyn and his Shadow Chancellor, John McDonnell, last week and over the weekend on how medical research is funded and on the Patent Box. We put out a press statement responding to Corbyn’s suggestion that medical research shouldn’t be “farmed out to big pharmaceutical companies like Pfizer” and offered to meet with the Labour leadership to help them understand our sector better. In January 2016, the BIA inputted into a Labour Party consultation on business incentives and were told that there would be further engagement on the findings so it is disappointing to see announcements about cancelling the Patent Box coming out in the current leadership contest. That said however it is also welcome to see various Labour politicians comment on the value of the Patent Box and the fact that this policy has its roots in Labour party policy development. We will continue to make contact with all policy makers throughout the Labour Party to communicate the value of our sector to the UK economy and how patients benefit from the innovative medical products being developed by BIA members.

The sector continues to pull together following the result of the EU Referendum. Some of you will have joined the webinar held on Friday to inform members about the formation of the UK EU Life Sciences Transition Programme – if you missed the webinar then you can listen again here. This key programme, taking place rapidly across the summer, is vital in bringing together key organisations from across the UK life sciences ecosystem to ensure that the priorities for the sector are prioritised in the new government’s negotiation over the UK’s future relationship with Europe.

In addition to this webinar, we would like to invite member companies to a ‘Town Hall’ style meeting at 3pm on Wednesday 27 July at our offices.  This meeting will provide the opportunity for BIA (and ABPI) members to hear about the processes and progress of the work, and to ask any questions that you may have.  Please confirm your attendance by completing the online form.

It’s vital that we have a forum such as this for detailed and dispassionate thinking around the areas that are key to our industry including regulation of medicine, access to the single market and talent, and intellectual property.  The BIA remains committed to making the UK the third global cluster for life sciences and we will work closely with government and relevant agencies to see how this ambition can be delivered in the new political context we now find ourselves in as a country.

The All-Party Parliamentary Group on Life Sciences, which the BIA supports along with ABPI, BIVDA and ABHI, held its AGM on Tuesday 19. We are grateful to its Chair, Kit Malthouse MP, who continues to be a strong champion for our sector, and would like to welcome Jo Churchill MP and Maggie Throup MP as new Vice-Chairs. All other Officers were re-elected and a work plan for the year was agreed, including events on the implications and opportunities of leaving the EU for the life sciences, immigration and skills supply, and the Accelerated Access Review.

This week the Home Office published the Statistics on the Use of Animals in Scientific Procedures for 2015 and you can read more about these on the BIA blog. Animal research plays an invaluable and legally-mandated part in the development of medicines. It is extremely important – and a legal obligation – for researchers to ensure that promising new medicines are tested for safety and efficacy (i.e. having the intended effects) as far as possible before they are tested in humans. The BIA is a signatory of the Concordat on Openness on the Use of Animals in Research, an agreement supported by a range of organisations – including universities, companies, research funders and umbrella organisations – to commit to being open about the use of animals in research in the UK.

It was excellent news to see that Duchenne muscular dystrophy (DMD) patients and their families welcome a decision by NICE making BIA member PTC Therapeutics’ Translarna available on the NHS. DMD is a muscle-wasting disease that usually affects boys in early childhood and is often fatal by age 30 and Translarna is currently the only treatment approved for marketing that addresses the underlying cause of the condition.

Year-on-year the BIA works in partnership with charities involved in research into some of today’s life changing illnesses. Over the past few years we have partnered with British Heart Foundation, Marie Curie Cancer Care, Bowel Cancer, Fight for Sight, CF Trust, Prostrate Cancer plus many more worthwhile causes. Applications are now invited from the charity sector to become the BIA Charity of the Year for 2017.  If you would like to be considered and work in partnership with the BIA in 2017 please contact us for more details. Deadline for submissions is Friday 12 August – send any applications through to esexton@bioindustry.org.

Finally, as many of you know, Pamela Learmonth will be leaving the BIA this week to go on maternity leave. I’m sure you will join me in wishing her well and we look forward to her return to the BIA in 2017. As I mentioned a few weeks back we are delighted to have welcomed Laura Collister to the team as Interim Head of Public Affairs and Communications and Laura will be a point of contact for members on this area of the BIA’s work in Pamela’s absence.

Best

Steve

This is Innovate UK’s 4th installment of their essential selection business tips and advice series. This video covers tips on business networking for start-ups and SMEs. Whether a start-up, small business or SME there may be useful advice that you haven’t considered.

The video outlines and explains the most effective ways for businesses to maximise their networking ROI, and includes actionable advice supported by comments from industry experts and investors.

On 7 July 2016, 35 senior representatives from the UK’s life science industry convened for the BIA’s sixteenth annual Parliament Day, a key day of engagement between BIA members and policymakers in Whitehall and Westminster.

Taking place just two weeks after the historic and marginal vote by the British public to leave the European Union – yet before the announcement of Theresa May as the next PM – Parliament Day 2016 was an especially timely opportunity for attendees to catch up, take stock, and hear the BIA’s and policymakers’ takes on next steps forward for the science and business environment post-Referendum.

For policymakers, it was an early opportunity to hear industry views and start to identify red-lines and potential areas of opportunity in this time of flux.

Naturally, the EU and Brexit permeated the discussions, but another important issue that was focused upon on Parliament Day was BIA’s recommendations on the development of innovation finance products; the call to refill the Biomedical Catalyst and key considerations for the shift from Innovate UK grants toward ‘non-grant’ or loan-style products. A short position paper is available online.

The delegation met with over 40 policymakers across over 20 meetings. This great level of engagement between BIA members and policymakers strengthens BIA’s relationship with key contacts in policy and political spheres. Following Theresa May’s instalment as the new UK Prime Minister and the subsequent changes to government staff, it was great to have Nicola Blackwood MP, newly appointed health minister, participating on the day. As well as being able to follow up with these contacts in the following weeks and months as BIA develops its post-Referendum work, we hope that the Parliament Day meetings will provide a stimulus for some parliamentary questions.

Photos of the day are available online.

 

Policymaker engagements (positions stated as of 7 July 2016):

  • George Freeman MP – Minister for Life Sciences, and Nicole Mather, Director of the Office for Life Sciences
  • Baroness Neville-Rolfe – Minister for Intellectual Property
  • Lord Hunt of King’s Heath – Opposition Spokesperson for Health
  • Ruth McKernan – Chief Executive, Innovate UK
  • Sir John Savill – Chief Executive, Medical Research Council
  • Nick Seddon – Special Adviser to No.10 (Health and Social Care)
  • Rachel Wolf – Special Adviser to No.10 (Technology, innovation, education)
  • Ed Jones – Special Adviser to Jeremy Hunt MP (Dept of Health)
  • HM Treasury’s Enterprise Investment Team
  • Department of Health’s R&D Directorate Team
  • Department of Business’s Innovation Finance Products Team
  • Department of Business’s Bioeconomy Team
  • NICE – Nick Crabb, Programme Director, Scientific Affairs; and Nina Pinwill, Associate Director, Office for Market Access

MPs:

  • Nicola Blackwood MP – Chair of the Science & Technology Committee, and Member for Oxford West and Abingdon (Con)
  • David Rutley MP – Member for Macclesfield (Con)
  • Liz McInnes MP – Member for Heywood and Middleton (Lab)
  • Rt Hon John Spellar MP – Member for Warley (Lab)
  • Chris Green MP – Member for Bolton West (Con)
  • Charles Walker OBE MP – Member for Broxbourne (Con)
  • Rt Hon Anne Milton MP – Member for Guildford (Con)
  • Jo Churchill MP – Member for Bury St Edmonds (Con)
  • Daniel Zeichner MP – Member for Cambridge (Lab)
  • Andrew Slaughter MP – Member for Hammersmith (Lab)

Peers:

  • Lord Turnberg
  • Lord Willetts
  • Lord Selborne
  • Lord Haskel
  • Baroness Sharp
  • Baroness Masham
  • Baroness Neville-jones
  • Lord Oxburgh
  • Lord Traverne

The Home Office has today published the Statistics on the Use of Animals in Scientific Procedures for 2015. The report shows 4.14 million procedures were conducted in 2015, representing an increase of 1%, or 21,000 procedures, compared with 2013.

Of the 4.14 million procedures, 2.08 million (just over 50%) were experimental procedures and 2.06 million (just under 50%) related to the creation and breeding of genetically altered animals – mostly mice – that were not used in further experimental procedures.

Trends over time

In 2014, the Home Office made some changes to how it collected the data for these statistics. This led to some misreporting for that year. The statistics published today have therefore been compared to 2013 rather than 2014 in the Home Office report.

The 2.08 million experimental procedures in 2015 represents an increase of 3% or 63,000 procedures compared with 2013. And the 2.06 million genetically altered animals created or bred but not used in further procedures in 2015 represents a decrease of 2% or 41,000 procedures compared with 2013.

This represents a slight change in the overall trend of how animals are being used as there has been a steady increase over the past decade in the use of genetically-altered animals. In between 2006 and 2013, the total number of all procedures increased by 37% (1.11 million procedures). The creation and breeding of genetically altered animals primarily accounted for this rise (1 million procedures) whilst the increase in the number of experimental procedures was much smaller (107,000 procedures).

Which species are used and how severe are the scientific procedures?

Of the 2.08 million experimental procedures completed in 2015, the majority involved mice (61% or 1.26 million procedures), followed by fish (14% or 294,000 procedures), rats (12% or 258,000 procedures) and birds (7% or 141,000 procedures). Experimental procedures involving specially-protected species (i.e. horses, dogs, cats, and non-human primates) accounted for just 0.8% (17,000) of procedures in 2015. There are additional standards for these animals and their use requires greater justification.

animal stats chart 2016

 

Nearly all of the procedures relating to the creation and breeding of genetically altered animals that were not used in further procedures involved mice (86% or 1.77 million procedures); zebrafish (13% or 267,000 procedures) and rats (1% or 11,000 procedures) were the second and third most-used species for genetic alteration.

One of the changes introduced in 2014 was the reporting of the actual severity of the procedure, which is assessed after the procedure is completed. This is more accurate than predicted severity, which is what was reported prior to 2014. However, this led to some misreporting in the 2014 dataset and today’s Home Office report does warn that some – but less – misreporting of these details will still be a problem in the 2015 dataset. It expects this to improve over successive years and says it has already improved guidance.

Of the severity assessments undertaken for the 2.08 million experimental procedures completed:

  • 13% (268,000) were assessed as sub-threshold (compared with 9% in 2014);
  • 6% (123,000) were assessed as non-recovery (compared with 7% in 2014);
  • 51% (1.06 million) were assessed as mild (compared with 51% in 2014);
  • 24% (502,000) were assessed as moderate (compared with 25% in 2014);
  • 6% (123,000) were assessed as severe (compared with 8% in 2014).

And of the severity assessments undertaken for genetic alteration procedures:

  • 55% (1.13 million) were assessed as sub-threshold (compared with 46% in 2014);
  • 2% (3,300) were assessed as non-recovery (compared with 0.1% in 2014);
  • 39% (806,000) were assessed as mild (compared with 48% in 2014);
  • 3% (65,000) were assessed as moderate (compared with 4% in 2014);
  • 3% (62,000) were assessed as severe (compared with 2% in 2014).

The report and associated data tables provide much greater detail about all species used, the severity of procedures, and changes on levels of their use over time.

What is the BIA’s position on animal research?

Animal research plays an invaluable and legally-mandated part in the development of medicines. It is extremely important – and a legal obligation – for researchers to ensure that promising new medicines are tested for safety and efficacy (i.e. having the intended effects) as far as possible before they are tested in humans.

concordat pic

The BIA is a signatory of the Concordat on Openness on the Use of Animals in Research, an agreement supported by a range of organisations – including universities, companies, research funders and umbrella organisations – to commit to being open about the use of animals in research in the UK.

The UK has among the highest standards in the world for the welfare of animals used in research, including a commitment to the 3Rs – the reduction, replacement and refinement of animals used in research. The BIA supports the aims of the Concordat, which will help the research community to communicate about the benefits, limitations and nature of animal research to ensure the public has the information they need to develop informed views on this topic.

MMIP banner

This is the latest update on the Medicines Manufacturing Industry Partnership (MMIP) from Chairman, Ian McCubbin. If you have any feedback on the content or information here then please email us at MMIP@bioindustry.org. If you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or sign up to our mailing list here.

Manufacturing output data

Recent data from the ONS UK Index of Production shows that pharmaceutical manufacturing saw an 8.6% rise in April 2016, it’s largest rise since July 2012. However, the latest data shows a decrease of 6.5%. The overall increase is understood to be caused by increased exports. Work is ongoing to better understand the UK pharmaceutical sector’s footprint, the causes of the volatility and what can be done to ensure the UK medicines manufacturing sector continues to thrive in the future.

Advanced Therapies Manufacturing Taskforce update

The Advanced Therapies Manufacturing Taskforce held its second meeting of three on Tuesday 28 June. Since the last meeting each of the three workstreams (International Competitiveness, Skills and People, Manufacturing and Technology) have held workshops and other engagement activity to develop a series of prioritised actions for the Taskforce meeting to consider. Work is in progress to ensure buy-in from relevant stakeholders and Government departments. The final meeting will take place in November.

New ABPI Head of Manufacturing Innovation

The ABPI has recently appointed a new Head of Manufacturing Innovation. Dr Magda Papadaki joins from Innovate UK where she was Lead Technologist for the Regenerative Medicine program. She is a trained stem cell and gene therapy scientist and has over a decade of experience in research, with regulatory and business experience in the EU and US.

She joins the rest of the MMIP operational team including Neil Baker from Pfizer, Gregor Anderson from GSK, Ian Dick from GSK and David Garton from AstraZeneca (left to right below).

MMIP team

Open Funding calls from Innovate UK and H2020

The KTN MedBio team has produced a blog highlighting a number of Innovate UK funding calls which are relevant to the sector. If you are interested and would like support to apply for any of these opportunities then please contact Mark Bustard at the KTN (mark.bustard@ktn-uk.org).

MHRA Innovation Office supports Queen’s University Belfast

Queen’s University Belfast has been developing novel patches that are showing considerable promise as an effective and safe platform for transdermal drug delivery, as well as for minimally-invasive patient monitoring/diagnosis. MHRA Innovation Office’s latest case study, looks at how they helped QUB in preparing for the regulatory framework that will be the final step in bringing innovation to market.

Consultations

  • MHRA consultation on guidance for medical devices
    The Medicines and Healthcare products Regulatory Agency is asking for comments on its draft guidance for medicinal devices. This guidance is intended to be a useful resource on human factors and usability engineering principles, to clarify the expectations of the regulatory bodies. It is aimed at manufacturers of all device classes who intend to market their device in the UK. The consultation closes on 5 August.
  • IMI consultation on advanced therapies
    IMI has developed a concept paper on advanced therapies. The aim of the concept paper is to identify the potential of IMI as a platform for enhancing ATMP research and development. The deadline for submitting comments is 25 July 2016.

I hope you find this note of interest and we will continue to communicate and create a community of committed like-minded professionals who can help with MMIP. Please contact us at MMIP@bioindustry.org or join our LinkedIn group at http://bia.me/MMIP_LinkedIn. Likewise, if you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or sign up to our mailing list here.

 

600 x 179 banner dotmailer

Following a swift change-over, Theresa May entered No. 10 last Wednesday as the new UK Prime Minister and proceeded to appoint her new cabinet. Some notable changes which are relevant to our sector include the movement of Greg Clark to head up the Department of Business, Energy and Industrial Strategy – a reform of BIS. Meanwhile Sajid Javid becomes Secretary of State for Communities and Local Government. Jeremy Hunt remains as Health Secretary and David Gauke becomes Chief Secretary to the Treasury.

Over the weekend, we saw a flurry of additional Ministerial appointments being announced. Of key interest to our sector, George Freeman has been moved from the Life Sciences brief to take up the role of Chair of the Prime Minister’s Policy Board. This is a key and central policy making position and great to have someone steeped with life sciences knowledge in this central role. Ministerial responsibilities are being confirmed as I write, so we do not yet have an absolute answer on whether the role held by Freeman will be replaced exactly and if not which Minister(s) will be responsible for life sciences and which Department(s) that will fall into. We know that Jo Johnson will retain his Universities and Science brief (but now working across both the Business and Education departments) and that other key faces for us will include newly appointed Health Ministers David Mowat and Nicola Blackwood. Nicola has engaged a lot with us recently, through her now prior role as Chair of the Science and Technology Select Committee but also as an Oxford MP, both at the recent BIA Parliament Day and at a private roundtable meeting in Oxford in May.

The new picture of government is further complicated by the fact that the shape of the new government currently features the creation of two new departments (the Department for Brexit and the Department for International Trade) and the demise or restructure of others (for example the absorption of the Department for Energy and Climate Change into the newly restructured Department for Business- now the Department for Business, Energy and Industrial Strategy rather than the Department for Business, Innovation and Skills). We will keep members updated as we know more, particularly how the changes will relate to how the new UK EU Life Sciences Steering Group will operate (see below) and our next policy and regulatory affairs update report due at the end of the month will provide a more detailed analysis of the new government landscape. In the meantime, this Politics Home article has a handy table of the appointments if you’re interested.

You may have seen some press coverage that following the outcome of the EU referendum, George Freeman MP, former Life Sciences Minister, announced the formation of the UK EU Life Sciences Steering Group to oversee and manage the transition for the life sciences sector. The Steering Group has asked the ABPI and BIA to set up and support a UK EU Life Sciences Transition Programme to do this work and the attached briefing sets out further information about the Programme and how you can become involved. This includes via a webinar on Friday 22 July 12-1pm – register to attend here.

In other developments following the EU Referendum, the MHRA released a new statement last week explaining that the Agency continues to play a full, active role in European regulatory procedures. Details are provided in the statement in full here, along with their initial response from 27 June.

Also on the MHRA, following our joint regulatory conference back in May, last week we published a report summarising the presentations and perspectives from senior experts and leading speakers from MHRA, the European Medicines Agency (EMA), the life science industry, National Institute for Health and Care Excellence (NICE), NHS England, academia, research charities, patient organisations and investment firms. The full report can be downloaded from the conference website, where you can also find the full programme and slide presentations for this year.

Finally, ending on some great news for the sector as MRC Technology announced it has monetised a portion of its royalty interest in leading cancer drug Keytruda – freeing up over £115M to expand its medical research activities. You can read about the role MRCT played in the development of the treatment in our Celebrate report. It’s fantastic to see the proceeds being reinvested in novel research and development – hopefully into the next Keytruda or two!

Best

Steve

If you didn’t manage to catch this Tuesday’s webinar, on raising capital in the current environment while retaining control, it’s now available to view below.

Hear from Darrin Disley on how Horizon Discovery was able to bring in different types of capital at different stages of the business; Harren Jhoti covers the potential of mergers and acquisitions following his experience at Astex Pharmaceuticals; and Neil Murray on the evolution of Redx Pharma and their collaboration with the NHS.

Do you have a video you would like the sector to see? Contact us.